Overall rank by patents
#25,215
Across all tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 14 technology areas, active 2016–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
The verdict
Szegedi holds 11 US patents across 14 technology areas, rank #25,215 of 50,000 tracked assignees.
Szegedi Tudományegyetem has been granted 11 US utility patents between 2016 and 2025, placing Szegedi Tudományegyetem at rank #25,215 across all assignees tracked by PlainPatent. This portfolio spans 14 distinct Cooperative Patent Classification (CPC) subclasses, averaging 14.6 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Szegedi Tudományegyetem is one of the more focused assignees in the PatentsView dataset. By volume, Szegedi sits between Sylvan R. Shemitz Designs, Inc. (11 patents, rank #25,211) and Salvia Bioelectronics B.v. (11 patents, rank #25,219) - the closest US assignees by grant volume. The composite Innovation Score of 30.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 3 grants, compared with 8 in the 2015–2019 window, a -62% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Szegedi Tudományegyetem's 14.6 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 14 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Szegedi Tudományegyetem against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
SYLVAN R. SHEMITZ DESIGNS, INC.
11 patents
SYNERSCOPE B.V.
11 patents
SYNOVA S.A.
11 patents
SYNTEST TECHNOLOGIES, INC.
11 patents
Sabre Industries Inc.
11 patents
Sage Global Services Limited
11 patents
Saitama University
11 patents
Salvia BioElectronics B.V.
11 patents
SZEGEDI TUDOMÁNYEGYETEM
11 patents
What this shows Szegedi holds 11 patents at rank #25,215, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Szegedi's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
31 Top 65% higher than 35% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 2 | 18.2% |
| 2017 | 5 | 45.5% |
| 2018 | 1 | 9.1% |
| 2020 | 2 | 18.2% |
| 2025 | 1 | 9.1% |
Top 14 of 14 technology areas
Overall rank by patents
#25,215
Across all tracked assignees
30.5 out of 100
How to use this portfolio
Szegedi's 11 grants land it in the top 65% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.